Akers Biosciences Inc (AKR)

 
This US company’s shares are traded by us as on the LSE. Income from them will not be treated as eligible for a reduced rate of tax. Learn more

AKR Share PerformanceMore

52 week high255.00 01/12/16
52 week low60.00 15/11/17
52 week change -139.00 (-71.28%)
4 week volume117,093 28/10/17

Media for (AKR)

Presenter: Ray, Akers, Co-Founder & Executive Chairman
28/07/2014
Presenter: Ray, Akers, Co-Founder & Executive Chairman
15/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Akers Bio revenues up 10%

Akers Biosciences' revenues rose by 10% to $675,831 in the third quarter as as increasing sales of its breathalyzer products an...

3rd Quarter Results

RNS Number: 5093W Akers Biosciences, Inc. 15 November 2017 November 15, 2017 This announcement contains inside information Akers Biosciences, Inc. Financial Results for the Third Quarter Ended September 30, 2017 Revenues up 10% as Breathalyzers and Cholesterol Tests Begin to Contribute Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers," "A...

Akers Bio sees new UK channel for breathalyzer

Akers Biosciences said Accutest Solutions, a distributor of the group's BreathScan alcohol detector in the UK, has secured a...

New UK Channel for Rapid Alcohol Breathalyzer

RNS Number: 3817W Akers Biosciences, Inc. 14 November 2017 November 14, 2017 Akers Biosciences, Inc. UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer Distributor Accutest Now Selling Through Today's Group Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ( " Akers Bio " or the "Company"), a developer of rapid health informatio...

Akers schedules results announcement

Akers Biosciences has confirmed that it intends to publish results for the three months ended 30 September on 15 Novemb...

Notice of Results

RNS Number: 3387W Akers Biosciences, Inc. 13 November 2017 November 13, 2017 Akers Biosciences, Inc. Notice of Q3 2017 Earnings Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ( " Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that the Company will publish its financial results in the United Kingdom fo...

Akers issues shares

Akers Biosciences confirmed that the Company has received conversion notices from warrant holders to convert into 337,2...

Issue of Equity

RNS Number: 9469V Akers Biosciences, Inc. 08 November 2017 November 8, 2017 Akers Biosciences, Inc. ("Akers Bio" or the "Company") Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (" Akers Bio " or the "Company"), a developer of rapid health information technologies, has received conversion notices from warrant holders in respect of...

Latest discussion posts More

  • Re: RNS : new PIFA agreement

    Maybe turned the corner here
    30-Mar-2017
    Silveroil
  • RNS : new PIFA agreement

    Looks like a potentially lucrative agreement with a group of up to 300 New York hospitals to introduce the PIFA ...
    19-Dec-2016
    gretel
  • Exciting RNS just out

    Worth noting in particular that First Check are a subsidiary of the mighty Alere ...
    1-Dec-2016
    gretel

Users' HoldingsMore

Users who hold Akers Biosciences Inc also hold..
LLOYDS GRP.29%
BP16%
ID:ISIN:GB00B142G99416%
NATIONAL GRID16%
GLAXOSMITHKLINE12%

Codes & Symbols

ISINUS00973E1029
SymbolsAKR, LSE:AKR, AKR.L, AKR:LN, LON:AKR, XLON:AKR

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account